1. Home
  2. ENTX vs AMTD Comparison

ENTX vs AMTD Comparison

Compare ENTX & AMTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • AMTD
  • Stock Information
  • Founded
  • ENTX 2010
  • AMTD 2003
  • Country
  • ENTX Israel
  • AMTD France
  • Employees
  • ENTX N/A
  • AMTD N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • AMTD
  • Sector
  • ENTX Health Care
  • AMTD
  • Exchange
  • ENTX Nasdaq
  • AMTD Nasdaq
  • Market Cap
  • ENTX 90.2M
  • AMTD 77.3M
  • IPO Year
  • ENTX 2018
  • AMTD 2019
  • Fundamental
  • Price
  • ENTX $2.10
  • AMTD $1.03
  • Analyst Decision
  • ENTX Strong Buy
  • AMTD
  • Analyst Count
  • ENTX 1
  • AMTD 0
  • Target Price
  • ENTX $10.00
  • AMTD N/A
  • AVG Volume (30 Days)
  • ENTX 70.9K
  • AMTD 42.3K
  • Earning Date
  • ENTX 03-07-2025
  • AMTD 12-30-2024
  • Dividend Yield
  • ENTX N/A
  • AMTD N/A
  • EPS Growth
  • ENTX N/A
  • AMTD N/A
  • EPS
  • ENTX N/A
  • AMTD N/A
  • Revenue
  • ENTX $99,000.00
  • AMTD $46,925,000.00
  • Revenue This Year
  • ENTX N/A
  • AMTD N/A
  • Revenue Next Year
  • ENTX N/A
  • AMTD N/A
  • P/E Ratio
  • ENTX N/A
  • AMTD $0.86
  • Revenue Growth
  • ENTX 607.14
  • AMTD N/A
  • 52 Week Low
  • ENTX $1.00
  • AMTD $0.96
  • 52 Week High
  • ENTX $3.35
  • AMTD $1.98
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 40.77
  • AMTD 45.44
  • Support Level
  • ENTX $2.20
  • AMTD $1.03
  • Resistance Level
  • ENTX $2.49
  • AMTD $1.13
  • Average True Range (ATR)
  • ENTX 0.22
  • AMTD 0.08
  • MACD
  • ENTX -0.03
  • AMTD 0.00
  • Stochastic Oscillator
  • ENTX 16.13
  • AMTD 30.04

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About AMTD AMTD IDEA Group each representing six (6)

AMTD IDEA Group is a financial institution operating in five business segments: The capital market solutions segment assists customers in raising funds through equity and debt financing, private placements, and debt issuances. The digital solutions and other services segment provides institutional and corporate clients with paid access to enhance investor communication and relations, corporate communication also provides digital financial solution services. The Media and entertainment segment offers print and digital advertising campaigns, licensing, and marketing services including branded content, video production. The hotel operations, hospitality, and VIP services segment engages in hotel investments, hotel operations, hospitality, and VIP services; and Strategic investment segment.

Share on Social Networks: